Product Description
Recombinant Human Murine Chimeric Anti CD20 Monoclonal Antibody Injection (Sourced from: https://clinicaltrials.gov/ct2/show/NCT02945215)
Mechanisms of Action: CD20 Inhibitor
Novel Mechanism: No
Modality: Antibody
Route of Administration: Intravenous
FDA Designation: *
Approval Status: Not Approved
Approved Countries: None
Approved Indications: None
Known Adverse Events: None
Company: M.D. Anderson Cancer Center
Company Location: Western America
Company Founding Year: 1941
Additional Commercial Interests: None
Clinical Description
Countries in Clinic:
Active Clinical Trial Count:
Recent & Upcoming Milestones
Highest Development Phases
Phase 3: Diffuse Large B-Cell Lymphoma|Myelodysplastic Syndrome|Acute Lymphoid Leukemia|Acute Myeloid Leukemia|Preleukemia|Precursor Cell Lymphoblastic Leukemia-Lymphoma
Phase 2: Acute Monocytic Leukemia|Anemia, Refractory, with Excess of Blasts|Histiocytosis, Langerhans-Cell|Chronic Myeloid Leukemia|Preleukemia|Chronic Myelomonocytic Leukemia|Myelodysplastic Syndrome|Juvenile Myelomonocytic Leukemia,|Myeloid, Accelerated Leukemia|T-Cell Cutaneous Lymphoma|Diffuse Large B-Cell Lymphoma|Chronic Lymphoid Leukemia|Inflammation|Biphenotypic Acute Leukemia|Acute Lymphoid Leukemia|Precursor Cell Lymphoblastic Leukemia-Lymphoma|Acute Myelomonocytic Leukemia|Follicular Lymphoma|Lymphoma, B-Cell|Multiple Myeloma|Lymphoma, Non-Hodgkin|Acute Myeloid Leukemia|Precursor B-Cell Lymphoblastic Leukemia-Lymphoma|B-Cell Leukemia|Myelogenous, Chronic, BCR-ABL Positive Leukemia|Myeloproliferative Disorders|Hodgkin Lymphoma|Myelodysplastic-Myeloproliferative Diseases|Leukemia, Plasma Cell|Lymphocytic Chronic B-Cell Leukemia
Phase 1: Multiple Myeloma|Leukemia, Plasma Cell|Acute Monocytic Leukemia|Lymphoma, Non-Hodgkin|Preleukemia|Chronic Myelomonocytic Leukemia|Precursor Cell Lymphoblastic Leukemia-Lymphoma|Precursor B-Cell Lymphoblastic Leukemia-Lymphoma|Anemia, Aplastic|Acute Myeloid Leukemia|Juvenile Myelomonocytic Leukemia,|Chronic Myeloid Leukemia|Acute Lymphoid Leukemia|Blast Crisis|Myelogenous, Chronic, BCR-ABL Positive Leukemia|Myeloproliferative Disorders|Lymphocytic Chronic B-Cell Leukemia|Lymphoma, B-Cell|Myelodysplastic Syndrome|Chronic Lymphoid Leukemia|Acute Myelomonocytic Leukemia|Biphenotypic Acute Leukemia|Adenocarcinoma|Diffuse Large B-Cell Lymphoma|Breast Cancer|B-Cell Marginal Zone Lymphoma|Mycosis Fungoides|T-Cell Cutaneous Lymphoma|Myeloid, Accelerated Leukemia
Trial ID |
Trial |
Phase |
Trial Status |
Disease |
Primary Completion Date |
Probability of Success |
Latest Trial Update Date |
Data Updated |
|---|---|---|---|---|---|---|---|---|
ACTRN12622000306718p |
2006-7041-83/hah | N/A |
Not yet recruiting |
Intestinal Diseases|Dental Caries |
2022-02-28 |
|||
NCT05052528 |
UCDCC#299 | P1 |
Recruiting |
Diffuse Large B-Cell Lymphoma |
2025-05-15 |
2024-05-14 |
||
NCT02960646 |
NCI-2016-01915 | P1 |
Completed |
Acute Myelomonocytic Leukemia|Chronic Lymphoid Leukemia|Myelodysplastic Syndrome|Chronic Myelomonocytic Leukemia|Leukemia, Plasma Cell|Myelogenous, Chronic, BCR-ABL Positive Leukemia|Precursor Cell Lymphoblastic Leukemia-Lymphoma|Acute Lymphoid Leukemia|Blast Crisis|Lymphoma, B-Cell|Lymphocytic Chronic B-Cell Leukemia|Chronic Myeloid Leukemia|Precursor B-Cell Lymphoblastic Leukemia-Lymphoma|Preleukemia|Acute Monocytic Leukemia|Myeloproliferative Disorders|Anemia, Aplastic|Lymphoma, Non-Hodgkin|Multiple Myeloma|Juvenile Myelomonocytic Leukemia,|Acute Myeloid Leukemia |
2023-02-13 |
2023-02-18 |
Primary Completion Date|Primary Endpoints|Study Completion Date|Treatments|Trial Status |
|
NCT03432741 |
MC1689 | P1 |
Terminated |
Lymphoma, Non-Hodgkin|Adenocarcinoma|B-Cell Marginal Zone Lymphoma|T-Cell Cutaneous Lymphoma|Breast Cancer|Mycosis Fungoides |
2022-08-26 |
2025-05-28 |
Primary Completion Date|Primary Endpoints|Treatments |
|
NCT01619761 |
NCI-2012-02071 | P1 |
Unknown status |
Acute Lymphoid Leukemia|Multiple Myeloma|Lymphocytic Chronic B-Cell Leukemia|Myeloid, Accelerated Leukemia|Chronic Lymphoid Leukemia|Acute Myeloid Leukemia|Myelogenous, Chronic, BCR-ABL Positive Leukemia|Precursor Cell Lymphoblastic Leukemia-Lymphoma|Lymphoma, Non-Hodgkin|Preleukemia|Precursor B-Cell Lymphoblastic Leukemia-Lymphoma|Lymphoma, B-Cell|Chronic Myeloid Leukemia|Leukemia, Plasma Cell|Myelodysplastic Syndrome|Biphenotypic Acute Leukemia |
2021-11-01 |
2022-02-02 |
Primary Endpoints|Treatments|Trial Status |
|
CTR20160770 |
CTR20160770 | P1 |
Completed |
Lymphoma, B-Cell |
2019-10-15 |
2025-04-29 |
Patient Enrollment|Treatments |
|
NCT02945215 |
CIBI301A201 | P1 |
Completed |
Lymphoma, B-Cell |
2019-03-21 |
2020-09-03 |
||
NCT02779283 |
IRB00011766 | P1 |
Completed |
Precursor Cell Lymphoblastic Leukemia-Lymphoma|Acute Myeloid Leukemia|Acute Lymphoid Leukemia |
2018-04-19 |
2025-02-07 |
Primary Endpoints|Treatments |
|
CTR20140762 |
CTR20140762 | P1 |
Completed |
Lymphoma, Non-Hodgkin |
2016-10-06 |
2025-04-29 |
Treatments |
|
NCT02727803 |
NCI-2016-00584 | P2 |
Recruiting |
Myelogenous, Chronic, BCR-ABL Positive Leukemia|Chronic Myeloid Leukemia|Myeloid, Accelerated Leukemia|Precursor Cell Lymphoblastic Leukemia-Lymphoma|Leukemia, Plasma Cell|Acute Myeloid Leukemia|Precursor B-Cell Lymphoblastic Leukemia-Lymphoma|Acute Lymphoid Leukemia|Biphenotypic Acute Leukemia|Juvenile Myelomonocytic Leukemia,|Myelodysplastic Syndrome|Chronic Myelomonocytic Leukemia|Myelodysplastic-Myeloproliferative Diseases|Multiple Myeloma|Anemia, Refractory, with Excess of Blasts|Chronic Lymphoid Leukemia|Lymphoma, Non-Hodgkin|Acute Monocytic Leukemia|Acute Myelomonocytic Leukemia|Preleukemia|B-Cell Leukemia|Myeloproliferative Disorders|Lymphoma, B-Cell |
2027-05-31 |
2025-05-10 |
Primary Completion Date|Primary Endpoints|Study Completion Date|Treatments |
|
NCT06834373 |
MC230813 | P2 |
Recruiting |
T-Cell Cutaneous Lymphoma|Follicular Lymphoma|Inflammation|Diffuse Large B-Cell Lymphoma|Lymphoma, Non-Hodgkin |
2027-03-03 |
2025-04-05 |
Primary Endpoints|Start Date|Treatments|Trial Status |
|
NCT03096782 |
NCI-2018-01236 | P2 |
Completed |
Lymphoma, Non-Hodgkin|Precursor B-Cell Lymphoblastic Leukemia-Lymphoma|Myelogenous, Chronic, BCR-ABL Positive Leukemia|Preleukemia|Acute Myeloid Leukemia|Chronic Myeloid Leukemia|Lymphoma, B-Cell|Lymphocytic Chronic B-Cell Leukemia|Myelodysplastic Syndrome|Hodgkin Lymphoma|Histiocytosis, Langerhans-Cell|Chronic Lymphoid Leukemia|Acute Monocytic Leukemia|Acute Lymphoid Leukemia|Anemia, Refractory, with Excess of Blasts|Chronic Myelomonocytic Leukemia|Precursor Cell Lymphoblastic Leukemia-Lymphoma|Myeloid, Accelerated Leukemia|Juvenile Myelomonocytic Leukemia,|Acute Myelomonocytic Leukemia|Biphenotypic Acute Leukemia |
2022-09-20 |
2023-06-30 |
Primary Endpoints |
|
NCT05457556 |
ASCT2031 | P3 |
Active, not recruiting |
Acute Myeloid Leukemia|Acute Lymphoid Leukemia|Myelodysplastic Syndrome|Preleukemia|Precursor Cell Lymphoblastic Leukemia-Lymphoma |
2026-06-30 |
2025-05-06 |
Primary Completion Date|Primary Endpoints|Study Completion Date|Treatments|Trial Status |
|
NCT02003222 |
NCI-2013-02229 | P3 |
Active, not recruiting |
Acute Lymphoid Leukemia|Precursor Cell Lymphoblastic Leukemia-Lymphoma |
2023-06-23 |
2025-02-07 |
Primary Endpoints|Treatments |
|
CTR20160493 |
CTR20160493 | P3 |
Completed |
Diffuse Large B-Cell Lymphoma |
2019-09-05 |
2025-04-29 |
Patient Enrollment|Treatments |
|
NCT02867566 |
CIBI301A301 | P3 |
Completed |
Diffuse Large B-Cell Lymphoma |
2019-09-05 |
2020-08-14 |
Patient Enrollment|Primary Completion Date|Primary Endpoints|Start Date|Study Completion Date |
